Mario Mandala (Mario Mandalá, M Mandalà, Mario Mandalà)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 29

Top Topics

Systematic Review

Brain Metastases

Top Venues

Journal for immunotherapy of cancer

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jeffrey S Weber, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stephane Dalle, C Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A Fecher, Michael Millward, Nikhil I Khushalani, Paola Queirolo, Georgina V Long, Maurice Lobo, Margarita Askelson, Paolo Antonio Ascierto, James M G Larkin
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Paolo Antonio Ascierto, Milena Casula, Jenny Bulgarelli, Marina Pisano, Claudia Piccinini, Luisa Piccin, Antonio Cossu, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Miriam Paone, Maria Grazia Vitale, Ignacio Melero Bermejo, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni, Giuseppe Palmieri
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. Nature communications 15 (1) (2024)
Filippo Ugolini, Anna Szumera-Ciećkiewicz, Gianna Baroni, Gabriella Nesi, Mario Mandala, Soldano Ferrone, Daniela Massi
Correction to: Differential HLA class I subunit (A, B, C heavy chain and β2-microglobulin) expression levels in normal tissues. Virchows Archiv : an international journal of pathology (2024)
Paolo Antonio Ascierto, Reinhard Dummer, Helen J Gogas, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B de Groot, Naoya Yamazaki, Carmen Loquai, Caroline Robert, Keith T Flaherty
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF -Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Alexander C J van Akkooi, Axel Hauschild, Georgina V Long, Mario Mandala, Michal Kicinski, Anne-Sophie Govaerts, Isabelle Klauck, Monia Ouali, Paul C Lorigan, Alexander M M Eggermont
COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future oncology (London, England) (2023)
Kohei Shitara, Maria Di Bartolomeo, Mario Mandala, Min-Hee Ryu, Christian Caglevic, Tomasz Olesiński, Hyun Cheol Chung, Kei Muro, Eray Goekkurt, Raymond S McDermott, Wasat Mansoor, Zev A Wainberg, Chie-Schin Shih, Julie Kobie, Michael Nebozhyn, Razvan Cristescu, Z Alexander Cao, Andrey Loboda, Mustafa Özgüroğlu
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. Journal for immunotherapy of cancer 11 (6) (2023)
James M G Larkin, Michele Del Vecchio, Mario Mandala, Helen J Gogas, Ana M Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Mark Ross Middleton, Jose Lutzky, Luis de la Cruz Merino, Petr Arenberger, Victoria Atkinson, Andrew G Hill, Leslie A Fecher, Michael Millward, Paul D Nathan, Nikhil I Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo Antonio Ascierto, Jeffrey S Weber
Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Michela Giustozzi, Cecilia Becattini, Fausto Roila, Giancarlo Agnelli, Mario Mandala
DOACs in patients with brain cancers, promising but still a long way to go. Blood advances (2022)
Reinhard Dummer, Keith T Flaherty, Caroline Robert, Ana M Arance, Jan Willem B de Groot, Claus Garbe, Helen J Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liszkay, Carmen Loquai, Mario Mandala, Dirk Schadendorf, Naoya Yamazaki, Alessandra di Pietro, Jean Cantey-Kiser, Michelle Edwards, Paolo Antonio Ascierto
COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Joanna Placzke, Pawel P Teterycz, Pietro Quaglino, Bozena Cybulska-Stopa, Marco Tucci, Marco Rubatto, Tomasz Skora, Valeria Interno, Magdalena Rosinska, Aneta Borkowska, Anna Szumera-Cieckiewicz, Mario Mandala, Piotr Lukasz Rutkowski
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report. Cancers 14 (23) (2022)
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Paolo Antonio Ascierto, Paul D Nathan, Piotr Lukasz Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandala, Paul C Lorigan, Pier Francesco Ferrucci, Jean-Jacques Grob, Nicolas Meyer, Helen J Gogas, Daniil Stroyakovskiy, Ana M Arance, Jan C Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (13) (2022)
Joanna Placzke, Pawel P Teterycz, Pietro Quaglino, Bozena Cybulska-Stopa, Marco Tucci, Marco Rubatto, Tomasz Skora, Valeria Interno, Magdalena Rosinska, Aneta Borkowska, Anna Szumera-Cieckiewicz, Mario Mandala, Piotr Lukasz Rutkowski
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report. Cancers 14 (23) (2022)
Jeffrey S Weber, Mario Mandala, Paolo Antonio Ascierto, James Larkin
Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al . Journal for immunotherapy of cancer 10 (1) (2022)
Mario Mandala, James Larkin, Paolo Antonio Ascierto, Michele Del Vecchio, Helen J Gogas, C Lance Cowey, Ana Arance, Stéphane Dalle, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion-Sileni, Ivan Marquez-Rodas, Marcus O Butler, Anna Maria Di Giacomo, Jose Lutzky, Luis De La Cruz-Merino, Victoria Atkinson, Petr Arenberger, Andrew Hill, Leslie Fecher, Michael Millward, Nikhil I Khushalani, Veerle de Pril, Maurice Lobo, Jeffrey S Weber
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. Journal for immunotherapy of cancer 9 (8) (2022)
Joanna Placzke, Pawel P Teterycz, Pietro Quaglino, Bozena Cybulska-Stopa, Marco Tucci, Marco Rubatto, Tomasz Skora, Valeria Interno, Magdalena Rosinska, Aneta Borkowska, Anna Szumera-Cieckiewicz, Mario Mandala, Piotr Lukasz Rutkowski
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report. Cancers 14 (23) (2022)
Joanna Placzke, Pawel P Teterycz, Pietro Quaglino, Bozena Cybulska-Stopa, Marco Tucci, Marco Rubatto, Tomasz Skora, Valeria Interno, Magdalena Rosinska, Aneta Borkowska, Anna Szumera-Cieckiewicz, Mario Mandala, Piotr Lukasz Rutkowski
The Analysis of Trends in Survival for Patients with Melanoma Brain Metastases with Introduction of Novel Therapeutic Options before the Era of Combined Immunotherapy-Multicenter Italian-Polish Report. Cancers 14 (23) (2022)
Filippo Ugolini, Anna Szumera-Ciećkiewicz, Gianna Baroni, Gabriella Nesi, Mario Mandala, Soldano Ferrone, Daniela Massi
Differential HLA class I subunit (A, B, C heavy chain and β 2 -microglobulin) expression levels in normal tissues. Virchows Archiv : an international journal of pathology (2022)
Paolo Antonio Ascierto, Mario Mandala, Pier Francesco Ferrucci, Massimo Guidoboni, Piotr Lukasz Rutkowski, Virginia Ferraresi, Ana M Arance, Michele Guida, Evaristo Maiello, Helen J Gogas, Erika Richtig, Maria Teresa Fierro, Celeste Lebbè, Hildur Helgadottir, Paola Queirolo, Francesco Spagnolo, Marco Tucci, Michele Del Vecchio, Maria Gonzales Cao, Alessandro Marco Minisini, Sabino De Placido, Miguel F Sanmamed, Domenico Mallardo, Marcello Curvietto, Ignacio Melero, Giuseppe Palmieri, Antonio M Grimaldi, Diana Giannarelli, Reinhard Dummer, Vanna Chiarion Sileni
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Riccardo Bonacina, Alice Indini, Gabriella Massazza, Eliana Rulli, Andrea Gianatti, Mario Mandala, null null
Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres. Journal of clinical pathology (2021)
Aljosja Rogiers, Ines Pires da Silva, Chiara Tentori, Carlo Alberto Tondini, Joseph M Grimes, Megan H Trager, Sharon H Nahm, Leyre Zubiri, Michael Manos, Peter Bowling, Arielle Elkrief, Neha Papneja, Maria Grazia Vitale, April A N Rose, Jessica S W Borgers, Severine Roy, Joanna Mangana, Thiago Pimentel Muniz, Tim Cooksley, Jeremy Lupu, Alon Vaisman, Samuel D Saibil, Marcus O Butler, Alexander M Menzies, Matteo S Carlino, Michael Erdmann, Carola Berking, Lisa Zimmer, Dirk Schadendorf, Laura Pala, Paola Queirolo, Christian Posch, Axel Hauschild, Reinhard Dummer, John Haanen, Christian U Blank, Caroline Robert, Ryan J Sullivan, Paolo Antonio Ascierto, Wilson H Miller, F Stephen Hodi, Karijn P M Suijkerbuijk, Kerry L Reynolds, Osama E Rahma, Paul C Lorigan, Richard D Carvajal, Serigne N Lô, Mario Mandala, Georgina V Long
Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Journal for immunotherapy of cancer 9 (1) (2021)
Piotr Lukasz Rutkowski, Alice Indini, Matilde De Luca, Barbara Merelli, Anna Mariuk-Jarema, Pawel Teterycz, Pawel Rogala, Iwona Lugowska, Bozena Cybulska-Stopa, Alice Labianca, Lorenza Di Guardo, Michele Del Vecchio, Jacopo Pigozzo, Giovanni Randon, Francesca Corti, Carlo Alberto Tondini, Eliana Rulli, Mario Mandala
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study. Journal for immunotherapy of cancer 8 (2) (2021)
Maria Gonzales Cao, Teresa Puertolas, Mar Riveiro, Eva Muñoz-Couselo, Carolina Ortiz, Roger Paredes, Daniel Podzamczer, Jose Luis Manzano, Jose Molto, Boris Revollo, Cristina Carrera, Lourdes Mateu, Sara Fancelli, Enrique Espinosa, Bonaventura Clotet, Javier Martinez-Picado, Pablo Cerezuela, Ainara Soria, Ivan Marquez-Rodas, Mario Mandala, Alfonso Berrocal, null null
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Journal for immunotherapy of cancer 9 (3) (2021)
Rocco Cappellesso, Filippo Nozzoli, Federica Zito Marino, Sara Simi, Francesca Castiglione, Vincenzo De Giorgi, Carlo Cota, Rebecca Senetta, Giosuè Scognamiglio, Anna Maria Anniciello, Anna Maria Cesinaro, Mario Mandala, Andrea Gianatti, Maria Gabriella Valente, Barbara Valeri, Angela Rita Sementa, Costantino Ricci, Barbara Corti, Giandomenico Roviello, Angelo Paolo Dei Tos, Renato Franco, Daniela Massi
NTRK Gene Fusion Detection in Atypical Spitz Tumors. International journal of molecular sciences 22 (22) (2021)
Alice Indini, Fausto Roila, Francesco Grossi, Daniela Massi, Mario Mandala
Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review. International journal of molecular sciences 23 (1) (2021)
Mario Mandala, Paul Lorigan, Matilde De Luca, Andrea Bianchetti, Barbara Merelli, Anna Cecilia Bettini, Lucia Bonomi, Sharon Nahm, Maria Grazia Vitale, Giorgia Negrini, Andrea Di Croce, Paolo Antonio Ascierto, Eliana Rulli, Carlo Alberto Tondini
SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study. Journal for immunotherapy of cancer 9 (2) (2021)
Lorenzo Salvati, Mario Mandala, Daniela Massi
Melanoma brain metastases: review of histopathological features and immune-molecular aspects. Melanoma management 7 (2) (2020)
F Portelli, F Galli, L Cattaneo, M Cossa, Vincenzo De Giorgi, G Forte, G Fraternali Orcioni, A Gianatti, A Indini, A Labianca, A Maurichi, B Merelli, M C Montesco, M Occelli, R Patuzzo, D Piazzalunga, J Pigozzo, Pietro Quaglino, Simone Ribero, R Salvatori, D Saraggi, P Sena, R Senetta, B Valeri, M Tanaka, M Fukayama, G Palmieri, Mario Mandala, D Massi, null null
The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI). The British journal of dermatology 184 (2) (2020)
Eliana Rulli, Lorenzo Legramandi, Lorenzo Salvati, Mario Mandala
The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. Cancer 125 (21) (2019)